| DTI in Children With Multiple Sclerosis (NCT02361697) | University Hospital Muenster | 2014-12-01 |
| Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis (NCT02369926) | Transparency Life Sciences | 2014-11-01 |
| BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon (NCT02247310) | Bayer | 2014-10-20 |
| Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis (NCT02580669) | University Hospital, Montpellier | 2014-06-16 |
| Safety and Efficacy of Fingolimod in MS Patients in China (NCT01941004) | Novartis Pharmaceuticals | 2014-06-01 |
| Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 (NCT02579681) | Biogen | 2014-04-30 |
| Rebif® Rebidose® Versus Rebiject II® Ease-of-Use (NCT02019550) | EMD Serono | 2014-03-01 |
| Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM (NCT05684016) | George Washington University | 2013-12-01 |
| A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) (NCT01808482) | GlaxoSmithKline | 2013-03-13 |
| Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis (NCT01772199) | GlaxoSmithKline | 2013-02-01 |
| Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (NCT02137707) | McGill University | 2012-11-01 |
| Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis (NCT02687919) | Amanda Irish | 2012-10-01 |
| Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis. (NCT02769767) | Instituto Jalisciense de Cancerologia | 2012-08-01 |
| Imaging of Intracerebral Inflammation in MS (NCT02305264) | Assistance Publique - Hôpitaux de Paris | 2012-03-19 |
| NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness (NCT01591551) | Cornerstone Health Care, PA | 2012-03-01 |
| Multiple Sclerosis and Progressive Resistance Training (NCT01518660) | University of Aarhus | 2012-02-01 |
| Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS) (NCT02280876) | Universidad Austral de Chile | 2012-01-01 |
| Worms for Immune Regulation of Multiple Sclerosis (NCT01470521) | University of Nottingham | 2011-12-01 |
| The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis (NCT01453868) | Nelson Mandela Metropolitan University | 2011-10-01 |
| Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis (NCT01435993) | GlaxoSmithKline | 2011-09-08 |
| Fingolimod -Response According to Coping - Evaluation (NCT01420055) | Novartis Pharmaceuticals | 2011-08-01 |
| Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients (NCT01417312) | Charite University, Berlin, Germany | 2011-07-01 |
| Healthy Volunteer Study Using 3 Different Formulations of Firategrast (NCT01416363) | GlaxoSmithKline | 2011-05-20 |
| QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea (NCT01071694) | Bayer | 2011-01-01 |
| A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. (NCT01466322) | GlaxoSmithKline | 2010-12-22 |
| Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health (NCT01667796) | Johns Hopkins University | 2010-11-01 |
| An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) (NCT01110993) | Merck KGaA, Darmstadt, Germany | 2010-11-01 |
| Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers (NCT01431937) | GlaxoSmithKline | 2010-10-10 |
| Melatonin in Relapsing-Remitting Multiple Sclerosis Patients (NCT01279876) | Tehran University of Medical Sciences | 2010-10-01 |
| A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (NCT01116427) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-09-01 |
| Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS) (NCT01143441) | National Institute of Neurological Disorders and Stroke (NINDS) | 2010-05-13 |
| Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place. (NCT01424462) | GlaxoSmithKline | 2010-04-19 |
| Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells (NCT01414634) | Universitätsklinikum Hamburg-Eppendorf | 2010-02-01 |
| An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters (NCT01112345) | Merck KGaA, Darmstadt, Germany | 2009-12-01 |
| Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant (NCT01392872) | University Hospital, Clermont-Ferrand | 2009-11-01 |
| Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis (NCT02275741) | Dr. med. Micha Loebermann | 2009-10-01 |
| Bayer/Cognitive Assessments With Multiple Sclerosis Subjects (NCT00888277) | University of Louisville | 2009-05-01 |
| Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® (NCT01075880) | Merck KGaA, Darmstadt, Germany | 2009-05-01 |
| Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study (NCT01628315) | University at Buffalo | 2009-03-01 |
| Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS) (NCT01080053) | Merck KGaA, Darmstadt, Germany | 2008-11-01 |
| Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (NCT01080027) | Merck KGaA, Darmstadt, Germany | 2008-10-01 |
| A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina (NCT01080001) | Merck KGaA, Darmstadt, Germany | 2008-08-01 |
| To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients (NCT01080040) | Merck KGaA, Darmstadt, Germany | 2008-08-01 |
| A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (NCT00676715) | Genentech, Inc. | 2008-07-17 |
| COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS (NCT00675883) | Biogen | 2008-05-01 |
| Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses (NCT00984984) | Rennes University Hospital | 2008-03-01 |
| Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis (NCT00595920) | Opexa Therapeutics, Inc. | 2007-11-01 |
| Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two (NCT00548405) | Genzyme, a Sanofi Company | 2007-10-01 |
| Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One (NCT00530348) | Genzyme, a Sanofi Company | 2007-08-01 |
| Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis (NCT01158183) | Bayer | 2007-07-01 |
| BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose (NCT00459667) | Bayer | 2007-05-01 |
| Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis (NCT00411723) | Artielle ImmunoTherapeutics | 2006-12-01 |
| A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis (NCT00441103) | Merck KGaA, Darmstadt, Germany | 2006-12-01 |
| A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis (NCT01142583) | Merck KGaA, Darmstadt, Germany | 2006-07-01 |
| Differential Immune Effects of Natalizumab (NCT00859482) | Cantonal Hospital of St. Gallen | 2006-07-01 |
| Phase I BP Interferon (IFN) Beta-004 (NCT02517788) | Centre Hospitalier Universitaire Vaudois | 2006-05-01 |
| Natalizumab Re-Initiation of Dosing (NCT00306592) | Biogen | 2006-03-01 |
| Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (NCT01134627) | Merck KGaA, Darmstadt, Germany | 2006-02-01 |
| A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone (NCT01142466) | Merck KGaA, Darmstadt, Germany | 2005-12-01 |
| An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy (NCT01141751) | Merck KGaA, Darmstadt, Germany | 2005-09-01 |
| Phase I BP Interferon (IFN) Beta-001 (NCT02515695) | Centre Hospitalier Universitaire Vaudois | 2005-05-01 |
| A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (NCT00213135) | EMD Serono | 2005-04-01 |
| Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients (NCT01201343) | Merck KGaA, Darmstadt, Germany | 2005-01-01 |
| Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis (NCT00097331) | GlaxoSmithKline | 2004-09-01 |
| Study Evaluating CCI-779 in Relapsing Multiple Sclerosis (NCT00228397) | Wyeth is now a wholly owned subsidiary of Pfizer | 2003-11-01 |
| BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients (NCT00099502) | Bayer | 2003-11-01 |
| Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis (NCT00071838) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-10-30 |
| Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability (NCT00242177) | University of Illinois at Chicago | 2003-10-01 |
| Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis (NCT00276341) | Ipsen | 2003-08-26 |
| Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis (NCT00235989) | Bayer | 2003-06-01 |
| AVONEX® Combination Trial - "ACT" (NCT00112034) | Biogen | 2003-06-01 |
| Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis (NCT00097760) | Biogen | 2003-06-01 |
| An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS (NCT00206648) | Bayer | 2003-03-01 |
| Safety of RG2077 in Patients With Multiple Sclerosis (NCT00076934) | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-01-01 |
| A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis (NCT00050778) | Genzyme, a Sanofi Company | 2002-12-01 |
| Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis (NCT00220779) | Grifols Therapeutics LLC | 2002-12-01 |
| Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis (NCT00587691) | Opexa Therapeutics, Inc. | 2002-07-01 |
| Treatment of Multiple Sclerosis Using Over the Counter Inosine (NCT00067327) | National Center for Complementary and Integrative Health (NCCIH) | 2002-02-01 |
| Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis (NCT00030966) | Biogen | 2002-01-01 |
| Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis (NCT00027300) | Biogen | 2001-11-01 |
| Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects (NCT00292253) | EMD Serono | 2001-01-01 |
| A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) (NCT00292266) | EMD Serono | 1999-11-01 |